Takeda Pharmaceutical Company Ltd. / HUTCHMED (China) Limited

Refractory metastatic colorectal cancer

153K US cases/yr · $13.0B Global colorectal cancer therapy market 2023 (USD MM) · 1130 Total Takeda-HUTCHMED deal size (USD MM, $400M upfront + up to $730M milestones)

Disease Overview

Colorectal cancer (CRC) is the third-most-commonly-diagnosed cancer in the United States, with approximately 153,020 new cases and 52,550 deaths estimated in 2023 (American Cancer Society 2023 Facts & Figures). Approximately 20-25% of patients present with metastatic disease, and an additional 25-30% of early-stage patients ultimately relapse to metastatic CRC (mCRC). Treatment algorithms for RAS/RAF wild-type mCRC typically combine fluoropyrimidine-oxaliplatin or irinotecan backbones (FOLFOX/FOLFIRI) with anti-VEGF bevacizumab or anti-EGFR cetuximab/panitumumab; RAS-mutant patients receive bevacizumab combinations. After progression through two to three lines of standard therapy, options for refractory mCRC have historically been limited to regorafenib (Stivarga, Bayer multi-TKI, approved 2012), trifluridine/tipiracil (Lonsurf, Taiho/Servier, approved 2015, with bevacizumab combination approved 2023), and now fruquintinib (Fruzaqla, approved November 2023). Median overall survival in refractory mCRC is approximately 7-9 months and declines at each line. Precision subsets: BRAF V600E mutants receive encorafenib + cetuximab; HER2-amplified receive tucatinib + trastuzumab; MSI-H receive pembrolizumab / nivolumab; KRAS G12C mutants receive sotorasib or adagrasib combinations.

Competitive Landscape

Refractory metastatic colorectal cancer is a rapidly fragmenting competitive set as precision-medicine subsets erode the 'all-comers' third-line market. Core third-line and beyond agents: fruquintinib / Fruzaqla (Takeda/HUTCHMED, oral selective VEGFR1/2/3 TKI, FDA-approved November 2023 based on FRESCO-2 overall-survival benefit); regorafenib / Stivarga (Bayer, oral multi-kinase TKI incl. VEGFR / KIT / RET / RAF, approved 2012); trifluridine/tipiracil / Lonsurf (Taiho / Servier, nucleoside analog combo, approved 2015, plus bevacizumab combination approved August 2023 based on SUNLIGHT Phase 3 OS benefit). Precision subsets eroding the all-comers pool: encorafenib + cetuximab (Pfizer / Array / Lilly, for BRAF V600E, approved BEACON CRC 2020); tucatinib + trastuzumab / Tukysa (Seagen / Pfizer, for HER2-amplified, approved MOUNTAINEER 2023); sotorasib / Lumakras + panitumumab (Amgen, KRAS G12C, Phase 3 CodeBreaK 300 positive 2023); adagrasib / Krazati + cetuximab (Bristol Myers Squibb / Mirati, KRAS G12C, Phase 3 KRYSTAL-10); pembrolizumab / Keytruda (Merck, MSI-H first-line, KEYNOTE-177); nivolumab + ipilimumab (BMS, MSI-H, CheckMate-8HW). Adjacent VEGFR-class agents in earlier lines: bevacizumab / Avastin, ramucirumab / Cyramza, ziv-aflibercept / Zaltrap. Pipeline: HER3 DXd ADCs, CEA / GUCY2C bispecifics (tusamitamab ravtansine, cibisatamab), and TROP2 ADC Trodelvy / sacituzumab govitecan. Fruquintinib's highly selective VEGFR1/2/3 profile translates to better tolerability than regorafenib and a positive Phase 3 FRESCO-2 OS readout, giving Takeda a $1B+ peak-sales opportunity in refractory CRC globally ex-China.